Who is sponsoring NCT02799030?

NCT02799030 is sponsored by Biofrontera Bioscience GmbH.

What condition does NCT02799030 study?

NCT02799030 studies Actinic Keratosis.

What drugs are being tested in NCT02799030?

Interventions: BF-200 ALA 1%, BF-200 ALA 3%, BF-200 ALA 10%.

What is the status of NCT02799030?

NCT02799030 is currently COMPLETED.

Last reviewed 2016-07-18 · How we verify

A Randomized Placebo-controlled Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis

NCT02799030 Phase 2 COMPLETED

This was a placebo controlled, double blind, randomized phase II dose-response study to evaluate the efficacy and safety of BF-200 ALA (containing the active ingredient 5 - aminolevulinic acid- ALA) used with photodynamic therapy (PDT) in patients with actinic keratosis (AK).

Details

Lead sponsor	Biofrontera Bioscience GmbH
Phase	Phase 2
Status	COMPLETED
Enrolment	105
Start date	2006-10
Completion	2007-03

Conditions

Actinic Keratosis

Interventions

BF-200 ALA 1%
BF-200 ALA 3%
BF-200 ALA 10%

Primary outcomes

Total clearance rate of AK lesions — 12 weeks after photodynamic therapy (PDT)
Total clearance rate of all AK lesions, defined as the percentage of baseline lesions within the target treatment areas showing complete remission at week 12 post treatment.